Sökning: WFRF:(Budaj Andrzej) > In patients with st...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05284naa a2200469 4500 | |
001 | oai:DiVA.org:uu-418944 | |
003 | SwePub | |
008 | 200909s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4189442 URI |
024 | 7 | a https://doi.org/10.1016/j.ahj.2020.04.0042 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a White, Harvey D.u Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.4 aut |
245 | 1 0 | a In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events |
264 | 1 | b Elsevier BV,c 2020 |
338 | a print2 rdacarrier | |
520 | a BackgroundIn patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke.MethodsEBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) <100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) < 7% and BP of <130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly.ResultsIn 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model.At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C < 70 mg/dL compared with LDL-C < 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c < 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE.ConclusionsMACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) and even lower with LDL-C < 70 mg/dL. MACE in patients with diabetes was lower with HbA1c < 7%. Achievement of targets is associated with improved patient outcomes. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
700 | 1 | a Stewart, Ralph A. H.u Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.4 aut |
700 | 1 | a Dolby, Anthony J.u Milpk Hosp, Johannesburg, South Africa.4 aut |
700 | 1 | a Stebbins, Amandau Duke Clin Res Inst, Duke Med, Durham, NC USA.4 aut |
700 | 1 | a Cannon, Christopher P.u Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Harvard Clin Res Inst, Boston, MA 02115 USA.4 aut |
700 | 1 | a Budaj, Andrzeju Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland.4 aut |
700 | 1 | a Linhart, Alesu Gen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic.4 aut |
700 | 1 | a Pais, Premu St Johns Res Inst, Bangalore, Karnataka, India.4 aut |
700 | 1 | a Diaz, Rafaelu Inst Cardiovasc Rosario, Estudios Cordiol Latinoamer, Rosario, Argentina.4 aut |
700 | 1 | a Steg, Philippe Gabrielu Hop Bichat Claude Bernard, AP HP, Paris, France.;Paris Univ, FACT French Alliance Cardiovasc Trials, INSERM, Paris, France.;Imperial Coll, Natl Heart & Lung Inst, Royal Brampton Hosp, London, England.4 aut |
700 | 1 | a Krug-Gourley, Sueu GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA.4 aut |
700 | 1 | a Granger, Christopher B.u Duke Clin Res Inst, Duke Med, Durham, NC USA.4 aut |
700 | 1 | a Hochman, Judith S.u NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.4 aut |
700 | 1 | a Koenig, Wolfgangu Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany.;Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.;German Ctr Cardiovasc Res, Heart Alliance, Partner Site Munich, Munich, Germany.4 aut |
700 | 1 | a Harrington, Robert A.u Stanford Univ, Stanford Ctr Clin Res, Dept Med, Stanford, CA 94305 USA.4 aut |
700 | 1 | a Held, Claes,d 1956-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)clahe947 |
700 | 1 | a Wallentin, Lars,d 1943-u Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall |
710 | 2 | a Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.b Milpk Hosp, Johannesburg, South Africa.4 org |
773 | 0 | t American Heart Journald : Elsevier BVg 225, s. 97-107q 225<97-107x 0002-8703x 1097-6744 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-418944 |
856 | 4 8 | u https://doi.org/10.1016/j.ahj.2020.04.004 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.